Traditional Chinese medicine as potential adjuvants for tumor vaccines: a review of types, mechanisms, and forms.
1/5 보강
Therapeutic cancer vaccines are increasingly recognized as a highly promising approach for tumor treatment; however, their clinical efficacy critically depends on the rational design of vaccine adjuva
APA
Cui Y, Gong L, et al. (2025). Traditional Chinese medicine as potential adjuvants for tumor vaccines: a review of types, mechanisms, and forms.. Frontiers in immunology, 16, 1661694. https://doi.org/10.3389/fimmu.2025.1661694
MLA
Cui Y, et al.. "Traditional Chinese medicine as potential adjuvants for tumor vaccines: a review of types, mechanisms, and forms.." Frontiers in immunology, vol. 16, 2025, pp. 1661694.
PMID
41451199
Abstract
Therapeutic cancer vaccines are increasingly recognized as a highly promising approach for tumor treatment; however, their clinical efficacy critically depends on the rational design of vaccine adjuvants. Natural compounds derived from Traditional Chinese Medicine (TCM) have emerged as attractive candidates for next-generation tumor vaccine adjuvants. In this review, we systematically summarize the chemical constituents of TCM-derived adjuvants reported in current research and categorize their mechanisms of action into four functional modalities: (i) immunostimulatory adjuvants that activate innate immune pathways; (ii) delivery-enhancing systems that improve antigen stability and facilitate targeting to antigen-presenting cells; (iii) integrated platforms that combine both immunostimulatory and delivery-enhancing functions; and (iv) other mechanisms involving non-canonical immunomodulatory activities. We further discuss current challenges in standardization, regulatory approval, and clinical translation, offering a roadmap for harnessing the potential of TCM in the rational design of cancer vaccines.
MeSH Terms
Humans; Cancer Vaccines; Adjuvants, Immunologic; Medicine, Chinese Traditional; Neoplasms; Animals; Drugs, Chinese Herbal
같은 제1저자의 인용 많은 논문 (5)
- Intrapleural anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer with malignant pleural effusion: a prospective, single-arm, single-center, phase I trial.
- ACSL4 as a potential ferroptosis target in hepatocellular carcinoma: from mechanisms to implications.
- Surgery-centered integrated strategies for personalized hepatocellular carcinoma care.
- Drug-Induced Interstitial Lung Disease: A Real-World Pharmacovigilance Study Based on an Adverse Event Reporting System.
- Antimicrobial use in pediatric hematopoietic stem cell transplantation in China: a retrospective multicenter cohort study.